The research of high-quality grinding technology of large-size Al2O3 single-crystal slice
Al<inf>2</inf>O<inf>3</inf> single crystal has the following unique physical properties of high hardness, high toughness, obvious pleochroism and high refractive index Etc. The paper introduced the processing property of Al<inf>2</inf>O<inf>3</inf> single crystal, described its grinding technology. Then analyzed the characteristics and status of grinding technology of the large-sized Al<inf>2</inf>O<inf>3</inf> single crystal, combined with the relational research, discussed the technology of the grinding stage. Finally the paper summarized a set of precise grinding technology of large-sized Al<inf>2</inf>O<inf>3</inf> slice.
ELID grinding of silicon wafers: A literature review
Silicon wafers are the most widely used substrates for fabricating integrated circuits. There have been continuous demands for higher quality silicon wafers with lower prices, and it becomes more and more difficult to meet these demands using current manufacturing processes. In recent years, research has been done on electrolytic in-process dressing (ELID) grinding of silicon wafers to explore its potential to become a viable manufacturing process. This paper reviews the literature on ELID grinding, covering its set-ups, wheel dressing mechanism, and experimental results. It also discusses the technical barriers that have to be overcome before ELID grinding can be used in manufacturing.
Multiple-dose pharmacokinetics of moxisylyte after oral administration to healthy volunteers.
The pharmacokinetics of moxisylyte in plasma and urine was investigated after oral administration. Twelve subjects were treated orally, twice daily with 240 mg of the drug for 6 days; on day 7, the subjects received a last dose of 240 mg of moxisylyte. Moxisylyte was assayed in plasma and urine by a specific HPLC method with fluorimetric detection. Moxisylyte was absorbed rapidly and changed to its metabolites immediately after drug administration; unchanged moxisylyte was not found in plasma. Two metabolites were found in plasma and urine: conjugated desacetylmoxisylyte (DAM) and the conjugate of desmethylated DAM (MDAM). The pharmacokinetic parameters determined after the first oral administration were not modified on multiple dosing. The apparent elimination half-lives of conjugated DAM and MDAM were 2.3 and 3.5 h, respectively. Elimination of these two metabolites in urine averaged 50 and 10%, respectively.